HAE today
$122.71+$2.17 (+1.80%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourBullish
1 hourBullish
15 minStrong Bullish
5 minAscending Triangle
Daily trend turns down below $115.50
Key levels
Resistance$132.00
Resistance$123.77
Support$116.68
Support$111.36
Latest news & SEC filings
AnalystHaemonetics receives revised ratings from two research firms
AnalystCitigroup keeps Buy rating on Haemonetics, lifts target to $149
AnalystBarrington Research keeps Outperform rating on Haemonetics, lifts target to $145
All HAE news →About Haemonetics
Haemonetics is a medical technology company that makes devices, software, and services for collecting and processing blood and plasma, and for supporting hospital care. It reports in three segments: Plasma, which sells automated plasma collection systems and donor management software to plasma centers; Blood Center, which supplies blood banks with collection and processing equipment; and Hospital, which offers vascular closure, sensor-guided guidewires, esophageal protection, hemostasis testing, cell salvage, and transfusion management products. Its buyers range from drugmakers and blood banks to hospitals and health systems, and it sells worldwide through its own sales force and independent distributors.
Based on the company's 10-K filed May 20, 2026.
NYSE · Healthcare
HAEMONETICS CORP (HAE)
What Is the Price Target for HAE?
SEPT Low Target
$80.00
SEPT Mid Target
$124.00
SEPT High Target
$140.00
Analyst Consensus
$124.00
Is HAE a Buy or Sell Right Now?
Thesis
- •Revenue growing -2.0% YoY with SLOWING trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for HAE.
Start Free Trial →Is HAE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$177.39
38
Moat Score
NONE
7/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with HAE?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Galvin Roy | officer | Sale | 146 | $17K | Oct 30, 2026 |
| Maunsell Farris Maryanne | officer | Sale | 259 | $18K | Jun 5, 2026 |
| Miller Laurie A. | officer | Sale | 313 | $22K | Jun 5, 2026 |
| Basil Michelle L | officer | Sale | 2,913 | $164K | May 15, 2026 |
| Chan Frank | officer | Sale | 546 | $31K | May 15, 2026 |
| DArecca James | officer | Sale | 2,505 | $141K | May 15, 2026 |
| Maunsell Farris Maryanne | officer | Sale | 197 | $11K | May 15, 2026 |
| Galvin Roy | officer | Sale | 879 | $49K | May 15, 2026 |
| Miller Laurie A. | officer | Sale | 948 | $53K | May 15, 2026 |
| Simon, Christopher | director officer | Sale | 9,681 | $545K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →HAE Growth Story
Revenue YoY
-2.0%
3yr Revenue CAGR
4.5%
EPS Growth YoY
-38.07%
FCF Growth YoY
82.8%
Revenue Trend
SLOWING
Dark Pool Trades for HAE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for HAE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:28:03 | $120.20 | 1,100 | $$132K | SELL |
| 21:00:37 | $120.54 | 2,019 | $$243K | SELL |
| 21:00:36 | $120.54 | 1,862 | $$224K | SELL |
| 20:37:02 | $121.42 | 1,192 | $$145K | BUY |
| 20:09:48 | $120.85 | 1,129 | $$136K | BUY |
5 dark pool trades shown · $$881K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for HAEMONETICS CORP (HAE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →HAE — frequently asked questions
What is HAE stock price today?
HAEMONETICS CORP (HAE) is at $122.71, up 1.80% (+$2.17) at the Nov 12, 2026 close.
Why is HAE stock moving today?
Latest HAE news — Nov 6, 2026: Haemonetics receives revised ratings from two research firms · Nov 6, 2026: Citigroup keeps Buy rating on Haemonetics, lifts target to $149
What is the HAE price target?
The average analyst price target for HAE is $124.00, ranging from $80 to $140, based on 10 analysts. Latest: Barrington Research maintains on Oct 9, 2026.
What do analysts rate HAE?
Analyst ratings for HAE: 2 Buy, 19 Hold, 0 Sell — consensus Hold.
Did HAE beat earnings?
HAE last reported on Aug 6, 2026: EPS $1.14 vs $1.07 expected — a beat of 6.5%.
What is HAE's P/E ratio?
HAE trades at a P/E of 61.6 vs a Healthcare average of 18.5.
Does HAE pay a dividend?
HAE does not currently pay a dividend.
How much debt does HAE have?
HAEMONETICS CORP reported $1.2B of debt and $223M of cash (Jun 27, 2026).
What are HAE support and resistance levels?
Support: $116.68, $111.36, $106.67. Resistance: $123.77, $132.00, $142.11.
What are insiders doing with HAE?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on HAE?
Nov 6, 2026: Haemonetics receives revised ratings from two research firms · Nov 6, 2026: Citigroup keeps Buy rating on Haemonetics, lifts target to $149 · Nov 6, 2026: Barrington Research keeps Outperform rating on Haemonetics, lifts target to $145